Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An announcement from United Therapeutics ( (UTHR) ) is now available.
United Therapeutics announced it will present an update on its business at the J.P. Morgan Healthcare Conference, highlighting its growth strategy and innovative pipeline. The company is progressing with its UKidney and miroliverELAP programs and anticipates several clinical and regulatory milestones over the next three years, reflecting its commitment to sustaining business growth and creating shareholder value.
More about United Therapeutics
United Therapeutics Corporation is a public benefit corporation focused on developing treatments for rare lung diseases, pediatric oncology, and organ and organ alternatives. The company has a robust commercial business in rare diseases, emphasizing innovation and addressing organ transplant shortages through its three waves of growth: foundation, innovation, and revolution.
YTD Price Performance: 1.32%
Average Trading Volume: 325,055
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $16.29B
See more data about UTHR stock on TipRanks’ Stock Analysis page.
